Neurogene (NGNE) Non-Current Debt (2013)

Neurogene (NGNE) reported Non-Current Debt of $2.0 million for Q4 2013.

Neurogene (NGNE) Non-Current Debt (2013) Analysis & Trends

Neurogene has reported Non-Current Debt for 1 years, with the latest figure at $2.0 million in Q4 2013.

For the quarter ending Q4 2013, Non-Current Debt changed N/A year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2013 stood at $2.0 million (changed N/A YoY), and the FY2013 full-year result was $2.0 million, changed N/A from the prior year.
Non-Current Debt for Q4 2013 stood at $2.0 million.
The five-year high for Non-Current Debt was $2.0 million in Q4 2013, with the low at $2.0 million in Q4 2013.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Neurogene	216.17 Mn	216.17 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2013	2.04 Mn
Dec 31, 2013	2.04 Mn